WFH/LinkedIn
Feb 28, 2026, 14:48
WFH Acknowledges BioMarin’s Decision to Discontinue ROCTAVIAN
World Federation of Hemophilia (WFH) shared a post on LinkedIn:
“WFH Statement: the WFH acknowledges BioMarin’s decision to discontinue ROCTAVIAN and the importance of this development for the hemophilia community.
We urge BioMarin and other gene therapy developers to continue rigorous long-term safety monitoring of all discontinued products, and to preserve and share relevant clinical data that can inform ongoing scientific understanding and support patient safety.
For the full WFH position and our emphasis on preserving data in the WFH Gene Therapy Registry, please read our complete statement here.”
Other articles about World Federation of Hemophilia on Hemostasis Today.
-
Jul 17, 2026, 23:05Leonardo Roever: New Perspectives on Thromboinflammation in Acute Ischemic Stroke
-
Jul 17, 2026, 22:36Maeva May: Start Your Stroke Research Career with a Stroke Association Fellowship
-
Jul 17, 2026, 20:19Thomas Muenzel: Proud to Deliver the Sylviane Lévy-Toledano Memorial Plenary Keynote Lecture at ISTH 2026
-
Jul 17, 2026, 20:16Karin Leiderman: Proud of Jamie Madrigal for Receiving the JTH Editors’ Award
-
Jul 17, 2026, 20:14Lily Bull: Presenting New Research and Building Connections at ISTH 2026
-
Jul 17, 2026, 20:12Modern Concepts in Traumatic Disseminated Intravascular Coagulation – JTH
-
Jul 17, 2026, 20:10Nahid A. Qushmaq: Science, Collaboration, and Inspiration at ISTH 2026
-
Jul 17, 2026, 18:20Sarah Jones: Bringing Vessel-on-a-Chip Research to ISTH 2026
-
Jul 17, 2026, 18:06Virginia Barras Sánchez: United by a Commitment to Hemophilia at ISTH 2026